[Survival and factors related to the survival of recurrent breast cancer patients--a study with quantification theory].
Survival and factors related to survival were determined, using quantification theory, in 41 patients with recurrent breast cancer treated by a multidisciplinary approach. Average survival was 33 +/- 22 months (average +/- standard deviation), 50% survival was 32 months and 49% survived for more than 36 months. The important survival factors were the histological stage and effective therapy. First recurrence sites, menopausal status, number of organs involved in cancer recurrence and histologic type were not important factors to the survival. Using these 6 factors, we can distinguish the long survival group from the short survival group with 75% accuracy. The cumulative correlation ratio was 0.764.
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality*; D011379:Prognosis; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate